Psy Therapeutics, Inc. announced it raised $2.77 Million in an initial filing from an offering of $20.4 Million

Company

Location

About

Psy Therapeutics is discovering and developing unique therapies to improve the lives of people and families affected by neuropsychiatric and neurodegenerative disorders. Our robust pipeline of novel small molecules applies innovative platform technologies to targets supported by clinical and preclinical science. This risk-contained approach has led to the discovery of highly brain penetrant and well-tolerated molecules that overcome the limitations of existing treatments. Psy’s mission-focused progress is driven by our team of accomplished biopharma executives, renowned clinicians, and neuroscience experts deeply committed to advancing mental and neurological health.